Results decent but shows the executive have not done a good job of setting guidance reasonably. Underlying growth in revenue is good, but just have to tighten a little on NPAT. Assuming the heat coming out of wages I would assume better cost control moving forward.
honestly pathology in this country is a bit of a cash cow. Management should be keeping it tight and getting ready for the next outbreak to manifest.
buying at this price, but a little side-eye at the board TBH.
cheers,
YS
Results decent but shows the executive have not done a good job...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$2.83 |
Change
0.000(0.00%) |
Mkt cap ! $555.7M | |||
| Open | High | Low | Value | Volume |
| $2.85 | $2.86 | $2.81 | $4.431M | 1.570M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 25431 | $2.81 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.86 | 11164 | 3 |
View Market Depth
| Last trade - 16.10pm 28/07/2025 (20 minute delay) ? |
| ACL (ASX) Chart |